| Name | Blarcamesine hydrochloride |
| Description | Blarcamesine hydrochloride (AVex-73 hydrochloride) is a Sigma-1 Receptor agonist (IC50: 860 nM). |
| Animal Research | Drugs (including Anavex 2-73) are solubilized in physiological saline at the concentration of 5?mg/mL.Male mice aged 7-9 weeks and weighing 32±2?g are used. Drugs (including Anavex 2-73) are brought up to each dose by dilution and injected in a volume of 100?μL/20?g body weight. Animals are used between days 1 and 9 after i.c.v. injections for behavioral testing or killed before biochemical measures. |
| In vivo | The pretreatment of Blarcamesine(1/3 mg/kg) dose-dependently reduces the scopolamine-induced alternation deficit. The pretreatment with Blarcamesine(>0.3 mg/kg) dose-dependently and significantly attenuates the impairments of step-through latency[1]. The Blarcamesine(1mg/kg) dose-dependently blocks the recognition memory deficit. One day after injections, the significant Aβ25-35-induced decrease in Akt phosphorylation is significantly attenuated by Blarcamesine(0.1/1mg/kg). Seven days after injections, Blarcamesineattenuates the decrease in Ser9 phosphorylation induced by the peptide (0.3/1mg/kg)[2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 55 mg/mL (173.04 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (6.29 mM), Sonication is recommended.
|
| Keywords | σ1 | Sigmareceptor | Sigma Receptor | Inhibitor | inhibit | Blarcamesine hydrochloride | Blarcamesine | AVex-73 Hydrochloride | AE-37 Hydrochloride | AE37 Hydrochloride | AE 37 Hydrochloride |
| Inhibitors Related | Amitriptyline | Cutamesine dihydrochloride | Opipramol | L-693,403 maleate | Noscapine | Oxeladin citrate | Amitriptyline hydrochloride | S1R agonist 2 | 4-PPBP maleate | Glycerol phenylbutyrate | Sigma-1 receptor antagonist 1 | AB21 HCl |
| Related Compound Libraries | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | Anti-Alzheimer's Disease Compound Library | Membrane Protein-targeted Compound Library | ReFRAME Related Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Bioactive Compounds Library Max | Preclinical Compound Library | GPCR Compound Library | Anti-Cancer Compound Library | Anti-Cancer Drug Library |
United States
